Observational study to determine the incidence of new-onset valvulopathy in patients treated with pergolide as second-line therapy for Parkinson's disease

Trial Profile

Observational study to determine the incidence of new-onset valvulopathy in patients treated with pergolide as second-line therapy for Parkinson's disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2007

At a glance

  • Drugs Pergolide (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 17 Jul 2007 Status changed from recruiting to completed
    • 10 Apr 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top